Proton Therapy for Skull Base Chordomas: An Outcome Study from the University of Florida Proton Therapy Institute

Abstract

Objectives Skull base chordoma is a rare, locally aggressive tumor located adjacent to critical structures. Gross total resection is difficult to achieve, and proton therapy has the conformal advantage of delivering a high postoperative dose to the tumor bed. We present our experience using proton therapy to treat 33 patients with skull base chordomas.

Design Retrospective outcomes study.

Setting University of Florida Proton Therapy Institute; 2007 to 2011.

Participants A total of 33 patients with skull base chordomas received postoperative three-dimensional conformal proton therapy. The patients were 79% male and 6% diabetic; 27% had received a gross total resection.

Main Outcome Measures The gross tumor/tumor bed received a dose between 77.4 CGE and 79.4 CGE. Local control and overall survival were tracked, and radiation toxicity was assessed using a modified Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme.

Results Median follow-up for all patients was 21 months. Local control and overall survival rates at 2 years were 86% and 92%, respectively. Grade 2 toxicity was observed in 18% of our cohort in the form of unilateral hearing loss partially corrected with a hearing aid. No grade 2 or higher optic or brainstem toxicities were observed.

Conclusions Proton therapy is an effective treatment modality for skull base chordomas.

Keywords

head and neck tumors - chordoma - outcomes - proton therapy - particle therapy

• References

• 1 Weber AL, Liebsch NJ, Sanchez R, Sweriduk Jr ST. Chordomas of the skull base. Radiologic and clinical evaluation. Neuroimaging Clin N Am 1994; 4 (3) 515-527
• 2 McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 2001; 12 (1) 1-11
• 3 Pai HH, Thornton A, Katznelson L , et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001; 49 (4) 1079-1092
• 4 Mendenhall WM, Mendenhall CM, Lewis SB, Villaret DB, Mendenhall NP. Skull base chordoma. Head Neck 2005; 27 (2) 159-165
• 5 Kamrin RP, Potanos JN, Pool JL. An evaluation of the diagnosis and treatment of chordoma. J Neurol Neurosurg Psychiatry 1964; 27: 157-165
• 6 Volpe NJ, Liebsch NJ, Munzenrider JE, Lessell S. Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. Am J Ophthalmol 1993; 115 (1) 97-104
• 7 Pamir MN, Kiliç T, Türe U, Ozek MM. Multimodality management of 26 skull-base chordomas with 4-year mean follow-up: experience at a single institution. Acta Neurochir (Wien) 2004; 146 (4) 343-354
• 8 Zorlu F, Gürkaynak M, Yildiz F, Oge K, Atahan IL. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol Sci 2000; 21 (4) 203-207
• 9 Forsyth PA, Cascino TL, Shaw EG , et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993; 78 (5) 741-747
• 10 Debus J, Schulz-Ertner D, Schad L , et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000; 47 (3) 591-596
• 11 Hasegawa T, Ishii D, Kida Y, Yoshimoto M, Koike J, Iizuka H. Gamma knife surgery for skull base chordomas and chondrosarcomas. J Neurosurg 2007; 107 (4) 752-757
• 12 Martin JJ, Niranjan A, Kondziolka D, Flickinger JC, Lozanne KA, Lunsford LD. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg 2007; 107 (4) 758-764
• 13 Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999; 175 (Suppl. 02) 57-63
• 14 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
• 15 Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer 1985; 56 (1) 182-187
• 16 Tai PT, Craighead P, Bagdon F. Optimization of radiotherapy for patients with cranial chordoma. A review of dose-response ratios for photon techniques. Cancer 1995; 75 (3) 749-756
• 17 al-Mefty O, Borba LA. Skull base chordomas: a management challenge. J Neurosurg 1997; 86 (2) 182-189
• 18 Gay E, Sekhar LN, Rubinstein E , et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995; 36 (5) 887-896 ; discussion 896–897
• 19 Hug EB, Loredo LN, Slater JD , et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91 (3) 432-439
• 20 Ares C, Hug EB, Lomax AJ , et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 2009; 75 (4) 1111-1118
• 21 Debus J, Hug EB, Liebsch NJ , et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997; 39 (5) 967-975
• 22 Devisetty K, Malyapa RS, Mendenhall WM. Tumors of the base of skull. In: Mehta M, , ed. Principles and Practice of Neuro-Oncology: A Multidisciplinary Approach. New York, NY: Demos Medical Publishing; 2011: 846-860